Should Investors Buy Moderna Stock for Its Coronavirus Vaccine?

Brian Orelli, PhD and Corinne Cardina, The Motley Fool
·3 min read

On the surface, Moderna (NASDAQ: MRNA) looks like a great growth stock backed by its coronavirus vaccine. And the biotech also has potential to use its messenger RNA technology to develop other vaccines in its pipeline.